EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Personalized treatment of neuropathic pain: Where are we now?

Didier Bouhassira, Nadine Attal

European Journal of Pain · 2023-10 · 27 (9) · 1084-1098

DOI: 10.1002/ejp.2120 ↗

At a glance

Übersichtsarbeit in European Journal of Pain, published online on 2023-04-28. Written by Didier Bouhassira and 1 co-authors. Institution: Inserm U987, UVSQ-Paris-Saclay University, Ambroise Pare Hospital, Boulogne-Billancourt, France. Major MEDLINE topics: Precision Medicine, Neuralgia. Cited 48 times so far (Crossref); 127 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

The treatment of neuropathic pain remains a major unmet need that the development of personalized and refined treatment strategies may contribute to address. Database In this narrative review, we summarize the various approaches based on objective biomarkers or clinical markers that could be used.

Results

In principle, the validation of objective biomarkers would be the most robust approach. However, although promising results have been reported demonstrating a potential value of genomics, anatomical or functional markers, the clinical validation of these markers has only just begun. Thus, most of the strategies documented to date have been based on the development of clinical markers. In particular, many studies have suggested that the identification of specific subgroups of patients presenting with specific combinations of symptoms and signs would be a relevant approach. Two main approaches have been used to identify relevant sensory profiles: quantitative sensory testing and specific patients reported outcomes based on description of pain qualities.

Conclusion

We discuss here the advantages and limitations of these approaches, which are not mutually exclusive. Significance Recent data indicate that various new treatment strategies based on predictive biological and/or clinical markers could be helpful to better personalized and therefore improve the management of neuropathic pain.

Subjects

MeSH terms (MEDLINE)

Precision MedicineNeuralgiaHumansBiomarkers

Substances

Biomarkers

Authors and institutions

  • Inserm U987, UVSQ-Paris-Saclay University, Ambroise Pare Hospital, Boulogne-Billancourt, France.

Cite

APA

Bouhassira, D., & Attal, N. (2023). Personalized treatment of neuropathic pain: Where are we now?. European Journal of Pain, 27(9), 1084-1098. https://doi.org/10.1002/ejp.2120

Vancouver

Bouhassira D, Attal N. Personalized treatment of neuropathic pain: Where are we now?. European Journal of Pain. 2023;27(9):1084-1098. doi:10.1002/ejp.2120

BibTeX
@article{Bouhassira2023,
  author = {Bouhassira, Didier and Attal, Nadine},
  title = {Personalized treatment of neuropathic pain: Where are we now?},
  journal = {European Journal of Pain},
  year = {2023},
  volume = {27},
  number = {9},
  pages = {1084--1098},
  doi = {10.1002/ejp.2120}
}
Start for free →